| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
USANA Health Sciences, Inc.$21.98
-0.05 (-0.23%)
F 17Pipeline Score Tools & Services · Commercial
Market Cap
346.00 M
EPS
0.48
P/E Ratio
39.42 $
Value Trade
1.82 M
SEC Financials
Q2 2026Dilution Risk
Revenue
250.22 M
Operating CF
9.76 M
Total Assets
738.97 M
Total Liabilities
144.18 M
Equity
543.55 M
D/E Ratio
12,345
4.58 %
Week
-3.5 %
1 Month
-7.46 %
3 Month
-0.43 %
6 Month
-81.85 %
5 Year
2,825.27 %
All Time
Cash Data
Cash Position
162.75 M
Monthly Burn
-
Runway
12,345 mo
Burn Trend
StableSEC Filing
May 12, 2026
Overview
Volume
69.85 K
52 Week Range
16.60 - 38.32
% held by Insiders
40.87 %
% held by Institutions
55.53 %
Enterprise Value
248.48 M
Total Shares
18.47 M
Short %
6.06 %
Float Shares
10.90 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for USANA Health Sciences, Inc.
74Total events
0Upcoming
2Tier-1 (high impact)
2017 – 2026Coverage
Event history 74
Dec 23, 2024
Dec 23, 2024
Drug Pipeline Intelligence
F17
Pipeline Score -
Pipeline ValueValuation Signal
0
Drugs Scored—
rNPV / MCap Top 14%
Micro Cap (rank 784 of 911)
Percentile RankUSANA Health Sciences, Inc. has significant pipeline risk (17/100).
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement | |
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement | |
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in USNA
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
USNA Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-07-17 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-07-17 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-07-17 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
USNAKevin Guest: World Cup Determination Shows the Power of Grit, Preparation, Persistence
Kevin Guest, CEO of USANA Health Sciences, draws parallels between World Cup athletes and personal success in his book, 'All the Right Reasons.' He emphasizes the importance of grit, discipline, and persistence in achieving goals. Guest outlines five actionable steps to apply The Piano Principle in life, highlighting the necessity of commitment and daily effort to realize one's dreams.
Read more →USNAUSANA Celebrates 10 Years of Making the World a Better Place During World Service Week
USANA marks 10 years of World Service Week, uniting its community for acts of kindness. This year, they aim to feed 20,000 families through donations. Activities include supporting vulnerable children, community enrichment, and educational empowerment. The USANA Foundation has significantly impacted lives globally with its sustainable food initiatives.
Read more →USNAUSANA's Celavive Contouring Face & Neck Crème Named Among Canada's Top Skincare Products
USANA Health Sciences announced that its Celavive Contouring Face & Neck Crème has been awarded the title of Best Neck & Décolleté Cream by The Beauty Awards Canada. This recognition underscores the product's innovative formulation and effectiveness in skincare. The award highlights USANA's dedication to quality and performance in the beauty industry.
Read more →USNAUSANA Earns Dual Best of State Honors for Product Innovation and Development
USANA has been awarded two Best of State honors in Salt Lake City, recognizing its CellSentials supplements and Research and Development team. This marks the tenth consecutive year for CellSentials and the eighth win for the R&D team. The awards highlight USANA's commitment to scientific rigor and product quality.
Read more →USNAKevin Guest Encourages Professionals to Prioritize Wellness During Professional Wellness Month
Kevin Guest, CEO of USANA Health Sciences, advocates for prioritizing wellness during Professional Wellness Month. He emphasizes that healthy habits enhance productivity and workplace culture. Guest encourages individuals to adopt simple daily practices, such as consistent sleep and building relationships, to improve both personal and professional well-being. He believes that recognizing individual contributions is essential for a thriving work environment.
Read more →USNAUSANA's People-First Culture Earns Spot on USA TODAY Top Workplaces List
USANA Health Sciences has been named one of the 2026 USA TODAY Top Workplaces, recognizing its commitment to a people-first culture. The award highlights USANA's strong employee benefits, including onsite health amenities and tuition reimbursement. This recognition is based on authentic employee feedback, showcasing the company's dedication to fostering a supportive workplace environment.
Read more →USNAUSANA Health Sciences Reports First Quarter 2026 Results
USANA Health Sciences has released its financial results for the first quarter of 2026. The report includes key performance metrics and insights into the company's operations. However, specific details regarding revenue, profit margins, or strategic initiatives were not provided in the article.
Read more →USNADocument USANA Health Sciences Reports First Quarter 2026 Results Company Continues to Make Significant Progress on Transformation to Becoming a Leading Omnichannel Health and Wellness Platform
USANA Health Sciences has released its financial results for the first quarter of 2026, reporting net sales of $250 million, unchanged from the previous year. However, the company experienced a decline in net earnings and diluted EPS, reflecting a shift in its business model towards an omnichannel strategy. Active customer numbers in the Core Nutritional segment fell, while other segments like Rise Wellness showed strong growth. Despite the overall mixed performance, USANA reiterated its fiscal guidance for 2026.
Read more →USNADuring National Show Your Smile Month, Kevin Guest Urges Leaders to Lift Others Daily
During National Show Your Smile Month, Kevin Guest, CEO of USANA Health Sciences, emphasizes the importance of smiling in leadership and personal interactions. He asserts that a genuine smile can lower stress, build trust, and enhance communication. Guest encourages individuals to incorporate smiling into their daily routines to foster better relationships and improve overall well-being.
Read more →USNAOne Capsule, Endless Glow--Radiant Skin Starts Within
USANA Health Sciences has launched Glow, its first skin supplement aimed at enhancing skin health from within. This innovative product features clinically studied ingredients designed to improve skin clarity, support collagen production, and protect against environmental stress. Clinical trials indicate significant improvements in skin radiance and uniformity among participants. Glow represents a shift towards internal solutions for skincare.
Read more →USNAUSANA Schedules First Quarter 2026 Earnings Release and Conference Call
USANA has announced the scheduling of its earnings release for the first quarter of 2026, along with a conference call. Specific details regarding the time and date of the call have not been provided. This event is part of USANA's regular financial reporting process.
Read more →USNAUSANA CEO Kevin Guest Calls for Daily Health Routines on World Health Day
On World Health Day, USANA CEO Kevin Guest advocates for a shift from awareness to execution in health routines. He emphasizes the importance of daily habits and personal accountability over mere knowledge. Guest argues that consistent actions, rather than intense but short-lived efforts, lead to lasting health improvements. His insights are aligned with principles from his book, promoting clarity of purpose and community support.
Read more →USNATested, Trusted, Approved: USANA CellSentials Earns ConsumerLab.com Seal of Approval for Purity and Potency
USANA's CellSentials supplement has received the ConsumerLab.com Seal of Approval, confirming its purity, potency, and label accuracy. This certification highlights the product's ability to support immune function and overall health by providing essential nutrients. USANA emphasizes its commitment to quality through rigorous testing and innovative formulations.
Read more →USNADocument USANA Health Sciences Reports Fourth Quarter and Full Year 2025 Results and Provides Fiscal Year 2026 Outlook
USANA Health Sciences reported its financial results for the fourth quarter and fiscal year 2025, highlighting a year-over-year net sales increase of 8%. However, the company experienced a net loss in Q4 and a decline in active customer numbers. USANA is optimistic about fiscal year 2026, projecting consolidated net sales to reach between $925 million and $1 billion, driven by expansion in its Hiya and Rise Wellness brands. The company aims to leverage its growth opportunities in the global health and wellness market while focusing on product innovation and technological advancements.
Read more →USNADocument Kevin Guest Returns to USANA Health Sciences as
USANA Health Sciences has announced Kevin Guest's return as CEO, succeeding Jim Brown, who stepped down after three years in the position. Guest has a long history with the company, including eight years as CEO and three years as Executive Chairman. The Board believes his leadership will enhance strategic growth opportunities for USANA. Guest expressed enthusiasm to lead the organization again, aiming for sustainable growth and leveraging the strength of the company’s sales team and science-based products.
Read more →USNADocument USANA Health Sciences Reports Third Quarter 2025 Results and Updates Full-Year Outlook
USANA Health Sciences reported a net loss of $6.5 million in Q3 2025, down from a profit of $10.6 million in the same quarter last year. Despite a 7% increase in net sales, the company is experiencing challenges with falling customer numbers and profitability. The recently launched Brand Partner compensation plan aims to revitalize sales performance and enhance partner productivity. Updates to the fiscal year 2025 outlook reflect anticipated lower earnings and revised net sales expectations.
Read more →USNADocument USANA Health Sciences Provides Preliminary Third Quarter Results
USANA Health Sciences reported preliminary third quarter results, revealing net sales of approximately $214 million, up from $200 million the previous year. However, earnings from operations fell sharply to $1.2 million, impacted by lower sales and productivity during a transition to a new Brand Partner compensation plan. The company identified significant challenges, including a higher effective income tax rate which jumped to 65%. Despite these difficulties, USANA remains optimistic about future sales growth, particularly for its Hiya direct-to-consumer business.
Read more →USNADocument USANA Health Sciences Reports Second Quarter 2025 Results and Reiterates Full-Year Outlook
USANA Health Sciences reported its second-quarter 2025 financial results, showcasing an 11% year-over-year increase in net sales, totaling $236 million. However, net earnings decreased slightly from $10.4 million to $9.7 million, with a reduction in the number of Active Customers for its direct selling business. The company reiterated its full-year outlook for 2025, projecting net sales growth and further reinforcing its comprehensive commercial strategy. Additionally, USANA's Hiya direct-to-consumer business continues to perform well, aided by a recent partnership with Disney.
Read more →USNADocument USANA Health Sciences Reports First Quarter 2025 Results and Reiterates Full-Year Outlook
USANA Health Sciences announced its fiscal Q1 2025 results, reporting net sales of $250 million, up 10% from the prior year. However, net earnings decreased significantly to $9.4 million compared to $16.5 million, highlighting challenges in profitability. Despite these setbacks, management reiterated the full-year outlook, underscoring confidence in their growth strategy and the performance of their newly acquired business, Hiya. The company also expressed concerns over the potential impact of global trade uncertainties on future operations.
Read more →USNADocument USANA Health Sciences Reports Fourth Quarter and Full Year 2024 Results and Provides Fiscal Year 2025 Outlook
USANA Health Sciences reported its financial results for Q4 and the full year 2024, indicating a decline in net sales and earnings compared to the previous year. The company acquired Hiya Health Products, contributing slightly to sales, and aims for growth in fiscal year 2025 with a positive outlook for net sales and earnings. Challenges remain, particularly in the Asia Pacific region, where customer acquisition has been difficult due to cautious consumer sentiment. Nonetheless, new strategies and the Hiya acquisition are expected to support future growth.
Read more →USNADocument USANA Health Sciences Announces Strategic Acquisition of Hiya Health Hiya is a fast-growing, emerging leader of high-quality children's health wellness products. Broadens USANA's reach into the highly attractive
USANA Health Sciences has announced the strategic acquisition of a 78.8% stake in Hiya Health for $205 million. This transaction, which closed on December 23, 2024, aims to enhance USANA's presence in the children's health and wellness market by leveraging Hiya's substantial customer base and successful subscription model. The acquisition is expected to immediately benefit USANA's 2025 adjusted EBITDA. Hiya's co-founders will continue to lead the brand, which positions itself as a leading player in the sector with significant growth potential.
Read more →USNADocument USANA Health Sciences Reports Third Quarter 2024 Results
USANA Health Sciences reported its financial results for the third quarter of 2024, showing net sales of $200 million compared to $213 million in the same quarter of 2023. The company also adjusted its fiscal year 2024 guidance downward for net sales and diluted EPS, reflecting ongoing challenges with customer acquisition and consumer spending. Despite these hurdles, management highlighted progress in key initiatives and product innovations aimed at enhancing business value. Active customer numbers also fell, indicating a need for more effective consumer engagement strategies.
Read more →USNADocument USANA Health Sciences Reports Second Quarter 2024 Results
USANA Health Sciences reported its second-quarter results for fiscal 2024, revealing a significant drop in net sales and earnings per share compared to the same quarter in the previous year. The company announced net sales of $213 million, down from $238 million in Q2 2023, and a diluted EPS of $0.54, a decrease of 39%. To address ongoing economic pressures, management has made strategic changes, including a restructure of the commercial team and an expansion into India. However, the company has lowered its fiscal year 2024 outlook due to a challenging operating environment and currency exchange pressures.
Read more →USNADocument USANA Health Sciences Reports First Quarter 2024 Results
USANA Health Sciences reported its fiscal Q1 2024 results, revealing net sales of $228 million, an 8% decline year-over-year. Despite challenges in several key markets, particularly marked by inflationary pressures, the company noted a successful sales initiative in mainland China which drove customer engagement and partially mitigated the downturn. The company affirmed its fiscal year outlook for sales and earnings per share ranging from $850 million to $920 million and $2.40 to $3.00, respectively. Active customers showed growth, with a slight increase to 494,000 this quarter.
Read more →USNAUSANA Health Sciences Reports Fourth Quarter and Fiscal Year 2023 Results SALT LAKE CITY--(BUSINESS WIRE)
USANA Health Sciences reported mixed financial results for the fourth quarter and fiscal year 2023. While fourth quarter net sales decreased to $221 million, the diluted EPS increased significantly to $0.87, surpassing previous year results. Looking ahead, USANA has provided guidance for fiscal year 2024 with expected net sales between $850 million and $920 million, amid anticipated challenging economic conditions. The company is optimistic about opening its market in India, which could foster future growth despite facing headwinds in various regions and a decline in overall annual sales compared to the previous year.
Read more →USNAUSANA Health Sciences Reports Third Quarter 2023 Results SALT LAKE CITY--(BUSINESS WIRE)
USANA Health Sciences reported third quarter results with net sales of $213 million, down from $233 million in Q3 2022. The diluted EPS also fell to $0.59 from $0.78 year-over-year. The company has narrowed its fiscal year 2023 outlook amid inflationary pressures and reduced promotional activity, but aims to capitalize on growth opportunities in the global nutrition category, including entering the Indian market. The outlook reflects challenges faced in various regions and foreign currency impacts, although they maintain a stable financial position.
Read more →USNAUSANA Health Sciences Reports Second Quarter Net Sales of $238 Million and Diluted EPS of $0.89 SALT LAKE CITY--(BUSINESS WIRE)
USANA Health Sciences reported second quarter net sales of $238 million and diluted EPS of $0.89, both declines from the previous year. The company updated its fiscal 2023 outlook, raising the lower end of its guidance for net sales and diluted EPS. Notably, USANA is preparing to enter the Indian market later this year, which the company believes will contribute to future growth. Despite the positive guidance update, revenue and active customer counts reflect significant year-over-year declines.
Read more →USNAUSANA Health Sciences Announces Plans to Expand into India SALT LAKE CITY--(BUSINESS WIRE)
USANA Health Sciences has announced plans to expand its operations into India by the end of the third quarter of 2023. This marks the company's first new market entry in five years, aiming to introduce its health and wellness products to a new demographic. While the expansion presents a long-term growth opportunity, USANA acknowledges the challenges of entering a new culture and will adopt a cautious approach in the rollout. The anticipated contribution from this market is expected to be limited in its initial fiscal year.
Read more →USNAUSANA Health Sciences Reports First Quarter Net Sales of $248 Million and Diluted EPS of $0.95 SALT LAKE CITY--(BUSINESS WIRE)
USANA Health Sciences reported first quarter net sales of $248 million and a diluted EPS of $0.95 for the period ending April 1, 2023. This marks a sequential improvement, with net sales increasing from the previous quarter and EPS rising significantly. However, there is a year-over-year decline in both net sales and active customers. The company has updated its fiscal 2023 guidance upward, reflecting better than expected performance, particularly in the Asia Pacific region where increased demand was noted.
Read more →USNAUSANA Health Sciences Announces CEO Transition Plan SALT LAKE CITY--(BUSINESS WIRE)
USANA Health Sciences announced a transition plan for its CEO, with Kevin Guest moving to Executive Chairman and Jim Brown appointed as the new CEO effective July 1, 2023. Kevin Guest, who has been with the company for over 30 years and CEO since 2015, will continue to play an integral role in the company’s strategy. Jim Brown, who has been with USANA for 15 years, is expected to lead the company into its next growth phase. Both leaders have expressed confidence in the company’s future success in health and wellness.
Read more →USNAUSANA Health Sciences Reports Fourth Quarter and Fiscal Year 2022 Results SALT LAKE CITY--(BUSINESS WIRE)
USANA Health Sciences reported its financial results for the fourth quarter and fiscal year 2022, showing a decline in both net sales and diluted EPS compared to the prior periods. Despite challenges, the company highlighted stabilization in active customer counts and increased demand in China due to changes in COVID policy. Their outlook for fiscal year 2023 remains cautious, reiterating projections for net sales and EPS while acknowledging inflationary pressures and a downturn in the active customer base. Management is focused on increasing customer numbers and long-term growth strategies including new market opportunities and digital initiatives.
Read more →USNAUSANA Health Sciences Provides Preliminary Fiscal Year 2022 Results and Issues Initial Fiscal Year 2023 Outlook SALT LAKE CITY--(BUSINESS WIRE)
USANA Health Sciences announced its preliminary results for fiscal year 2022, reporting net sales of approximately $995 million and diluted EPS of about $3.65. The company provided initial guidance for fiscal year 2023, projecting net sales between $850 million and $950 million along with diluted EPS of $2.35 to $3.30. Key factors influencing this guidance include the company's strategy to grow its Active Customer base and various uncertainties in the economic environment, particularly in Asia Pacific markets. USANA plans to execute several strategic initiatives to enhance customer engagement and expand their market presence.
Read more →USNAUSANA Health Sciences Reports Third Quarter Results SALT LAKE CITY--(BUSINESS WIRE)
USANA Health Sciences Reports Third Quarter Results SALT LAKE CITY--(BUSINESS WIRE)--October 25, 2022--USANA Health Sciences, Inc. (NYSE: USNA) today announced financial results for its fiscal third quarter ended October 1, 2022. Key Financial & Operating Results Third quarter
Read more →USNAJ. Scott Nixon, CPA Rejoins USANA Health Sciences' Board of Directors SALT LAKE CITY--(BUSINESS WIRE)
J. Scott Nixon, CPA Rejoins USANA Health Sciences' Board of Directors SALT LAKE CITY--(BUSINESS WIRE)--July 27, 2022--USANA Health Sciences, Inc. (NYSE: USNA) today announced that J. Scott Nixon, CPA has rejoined the Company's Board of Directors effective July 25, 2022. Mr. Nixo
Read more →USNAUSANA Health Sciences Reports Second Quarter Results SALT LAKE CITY--(BUSINESS WIRE)
USANA Health Sciences Reports Second Quarter Results SALT LAKE CITY--(BUSINESS WIRE)--July 26, 2022--USANA Health Sciences, Inc. (NYSE: USNA) today announced financial results for its fiscal second quarter ended July 2, 2022. Key Financial & Operating Results Second quarter ne
Read more →USNAUSANA Health Sciences Provides Preliminary Second Quarter Results and Updates Fiscal Year 2022 Outlook SALT LAKE CITY--(BUSINESS WIRE)
USANA Health Sciences Provides Preliminary Second Quarter Results and Updates Fiscal Year 2022 Outlook SALT LAKE CITY--(BUSINESS WIRE)--July 6, 2022--USANA Health Sciences, Inc. (NYSE: USNA) today announced preliminary results for the second quarter ended July 2, 2022, and provi
Read more →USNAUSANA Health Sciences Reports First Quarter Results SALT LAKE CITY--(BUSINESS WIRE)
USANA Health Sciences Reports First Quarter Results SALT LAKE CITY--(BUSINESS WIRE)--April 26, 2022--USANA Health Sciences, Inc. (NYSE: USNA) today announced financial results for its fiscal first quarter ended April 2, 2022. Key Financial & Operating Highlights First quarter
Read more →USNAUSANA Health Sciences Reports Fiscal Year and Fourth Quarter 2021 Results SALT LAKE CITY--(BUSINESS WIRE)
USANA Health Sciences Reports Fiscal Year and Fourth Quarter 2021 Results SALT LAKE CITY--(BUSINESS WIRE)--February 8, 2022--USANA Health Sciences, Inc. (NYSE: USNA) today announced financial results for its full year and fiscal fourth quarter ended January 1, 2022. Key Financi
Read more →USNAXia Ding Named to USANA Health Sciences' Board of Directors SALT LAKE CITY--(BUSINESS WIRE)
Xia Ding Named to USANA Health Sciences' Board of Directors SALT LAKE CITY--(BUSINESS WIRE)--October 12, 2021--USANA Health Sciences, Inc. (NYSE: USNA) today announced the appointment of Xia Ding to the company's board of directors effective October 11, 2021. Ms. Ding currently
Read more →USNAUSANA Health Sciences Provides Preliminary Third Quarter Results and Updates Fiscal Year 2021 Outlook; Increases Share Repurchase Authorization SALT LAKE CITY--(BUSINESS WIRE)
USANA Health Sciences Provides Preliminary Third Quarter Results and Updates Fiscal Year 2021 Outlook; Increases Share Repurchase Authorization SALT LAKE CITY--(BUSINESS WIRE)--September 16, 2021--USANA Health Sciences, Inc. (NYSE: USNA) today announced preliminary third quarter
Read more →USNAUSANA Health Sciences Reports Record Second Quarter Results and Reiterates Growth Outlook for FY 2021 SALT LAKE CITY--(BUSINESS WIRE)
USANA Health Sciences Reports Record Second Quarter Results and Reiterates Growth Outlook for FY 2021 SALT LAKE CITY--(BUSINESS WIRE)--July 27, 2021--USANA Health Sciences, Inc. (NYSE: USNA) today announced record financial results for its fiscal second quarter ended July 3, 202
Read more →USNAUSANA Announces Formation of Board Sustainability Committee SALT LAKE CITY--(BUSINESS WIRE)
USANA Announces Formation of Board Sustainability Committee SALT LAKE CITY--(BUSINESS WIRE)--February 16, 2021--USANA (NYSE: USNA), USANA Health Sciences, Inc. today announced that its Board of Directors has formed a Sustainability Committee to oversee and advise on all matters
Read more →USNAUSANA Health Sciences Finishes Strong 2020 with 14.5% Fourth Quarter Net Sales Growth and 32.6% Diluted EPS Growth SALT LAKE CITY--(BUSINESS WIRE)
USANA Health Sciences Finishes Strong 2020 with 14.5% Fourth Quarter Net Sales Growth and 32.6% Diluted EPS Growth SALT LAKE CITY--(BUSINESS WIRE)--February 9, 2021--USANA Health Sciences, Inc. (NYSE: USNA) today announced financial results for its fiscal fourth quarter and full
Read more →USNAUSANA Health Sciences Reports Strong Third Quarter Growth; Raises Full-Year 2020 Net Sales and EPS Outlook SALT LAKE CITY--(BUSINESS WIRE)
USANA Health Sciences Reports Strong Third Quarter Growth; Raises Full-Year 2020 Net Sales and EPS Outlook SALT LAKE CITY--(BUSINESS WIRE)--October 20, 2020--USANA Health Sciences, Inc. (NYSE: USNA) today announced financial results for its fiscal third quarter ended September 2
Read more →USNAUSANA Health Sciences Announces Appointment of John T. Fleming to Board of Directors SALT LAKE CITY--(BUSINESS WIRE)
USANA Health Sciences Announces Appointment of John T. Fleming to Board of Directors SALT LAKE CITY--(BUSINESS WIRE)--September 8, 2020--USANA Health Sciences, Inc. (NYSE: USNA) today announced the appointment of John T. Fleming to the company's board of directors effective Sept
Read more →USNAUSANA Health Sciences Announces Increased Share Repurchase Authorization To $130 Million SALT LAKE CITY--(BUSINESS WIRE)
USANA Health Sciences Announces Increased Share Repurchase Authorization To $130 Million SALT LAKE CITY--(BUSINESS WIRE)--February 5, 2020--USANA Health Sciences, Inc. (NYSE: USNA) today announced that the Company's Board of Directors has authorized up to $130 million in share r
Read more →USNAUSANA Health Sciences Reports Fourth Quarter and Full-Year 2019 Results Fourth quarter net sales of $271.3 million Fourth quarter net earnings of $30.8 million, or $1.41 per share Fiscal year net sales of $1.061 billion
USANA Health Sciences Reports Fourth Quarter and Full-Year 2019 Results Fourth quarter net sales of $271.3 million Fourth quarter net earnings of $30.8 million, or $1.41 per share Fiscal year net sales of $1.061 billion Fiscal year net earnings of $100.5 million, or $4.41 per
Read more →USNAUSANA Health Sciences Announces Retirement of Founder and Chairman, Myron W. Wentz, Ph.D., from Chairman of the Board of Directors SALT LAKE CITY--(BUSINESS WIRE)
USANA Health Sciences Announces Retirement of Founder and Chairman, Myron W. Wentz, Ph.D., from Chairman of the Board of Directors SALT LAKE CITY--(BUSINESS WIRE)--December 18, 2019--USANA Health Sciences, Inc. (NYSE: USNA) today announced that the Company's founder and Chairman
Read more →USNAUSANA Health Sciences Announces Appointment of Timothy Wood, Ph.D., to Board of Directors and Promotion of Walter Noot to Chief Operating Officer SALT LAKE CITY--(BUSINESS WIRE)
USANA Health Sciences Announces Appointment of Timothy Wood, Ph.D., to Board of Directors and Promotion of Walter Noot to Chief Operating Officer SALT LAKE CITY--(BUSINESS WIRE)--October 24, 2019--USANA Health Sciences, Inc. (NYSE: USNA) today announced the appointment of Timoth
Read more →USNAUSANA Health Sciences Reports Third Quarter 2019 Results Third quarter net sales of $260.6 million Third quarter net earnings of $24.2 million, or $1.09 per diluted share Company narrows 2019 Net Sales and EPS outlook on
USANA Health Sciences Reports Third Quarter 2019 Results Third quarter net sales of $260.6 million Third quarter net earnings of $24.2 million, or $1.09 per diluted share Company narrows 2019 Net Sales and EPS outlook on updated FX outlook for the year SALT LAKE CITY--(BUSINE
Read more →USNAUSANA Health Sciences Provides Preliminary Second Quarter Results and Updates Fiscal Year 2019 Outlook SALT LAKE CITY--(BUSINESS WIRE)
USANA Health Sciences Provides Preliminary Second Quarter Results and Updates Fiscal Year 2019 Outlook SALT LAKE CITY--(BUSINESS WIRE)--July 2, 2019--USANA Health Sciences, Inc. (NYSE: USNA) today announced preliminary second quarter results and updated its outlook for fiscal ye
Read more →USNAUSANA Health Sciences Reports Second Quarter 2019 Results Second quarter net sales of $256.0 million Second quarter net earnings of $21.4 million, or $0.91 per diluted share Company reiterates 2019 Net Sales and EPS outl
USANA Health Sciences Reports Second Quarter 2019 Results Second quarter net sales of $256.0 million Second quarter net earnings of $21.4 million, or $0.91 per diluted share Company reiterates 2019 Net Sales and EPS outlook provided on July 2, 2019 Conference call on July 24,
Read more →USNAUSANA Health Sciences Reports First Quarter 2019 Results Results in-line with preliminary results provided on
USANA Health Sciences Reports First Quarter 2019 Results Results in-line with preliminary results provided on April 2, 2019 First quarter net sales of $273.0 million First quarter net earnings of $24.2 million, or $1.01 per share Company reiterates 2019 outlook provided in ea
Read more →USNAUSANA Health Sciences Provides Preliminary First Quarter Net Sales and Updates Fiscal Year 2019 Outlook SALT LAKE CITY--(BUSINESS WIRE)
Health Sciences Provides Preliminary First Quarter Net Sales and Updates Fiscal Year 2019 Outlook SALT LAKE CITY--(BUSINESS WIRE)--April 2, 2019--USANA Health Sciences, Inc. (NYSE: USNA) today announced preliminary first quarter net sales and updated its outlook for fiscal ye
Read more →USNAUSANA Health Sciences Reports Record Full-Year 2018 Results Record fiscal year net sales of $1.189 billion, an increase of 13.6% Record fiscal year net earnings of $126.2 million, or $5.12 per share Fourth quarter net sa
USANA Health Sciences Reports Record Full-Year 2018 Results Record fiscal year net sales of $1.189 billion, an increase of 13.6% Record fiscal year net earnings of $126.2 million, or $5.12 per share Fourth quarter net sales of $299.0 million, an increase of 9.5% year-over-year
Read more →USNAUSANA Health Sciences Announces Appointment of Peggie Pelosi to Board of Directors SALT LAKE CITY--(BUSINESS WIRE)
Health Sciences Announces Appointment of Peggie Pelosi to Board of SALT LAKE CITY--(BUSINESS WIRE)--December 19, 2018--USANA Health Sciences, Inc. (NYSE: USNA) today announced the appointment of Peggie Pelosi to the company's board of directors effective December 19, 2018. Ms
Read more →USNAUSANA Health Sciences Reports Results for Third Quarter 2018; Updates 2018 Outlook; Board Increases Share Repurchase Authorization Third quarter net sales of $296.8 million, an increase of 13.4% year-over-year Third quar
USANA Health Sciences Reports Results for Third Quarter 2018; Updates 2018 Outlook; Board Increases Share Repurchase Authorization Third quarter net sales of $296.8 million, an increase of 13.4% year-over-year Third quarter diluted earnings per share increased 27.8% year-over-y
Read more →USNAUSANA Health Sciences Reports Record Results for Second Quarter 2018; Increases 2018 Outlook Record second quarter net sales of $301.5 million, an increase of 17.3% year-over-year Second quarter diluted earnings per shar
USANA Health Sciences Reports Record Results for Second Quarter 2018; Increases 2018 Outlook Record second quarter net sales of $301.5 million, an increase of 17.3% year-over-year Second quarter diluted earnings per share increased 46.2% year-over-year to $1.36 per share SALT
Read more →USNAUSANA Health Sciences Reports Record First Quarter 2018 Net Sales and Increases 2018 Outlook Record first quarter net sales of $292.0 million, an increase of 14.4% year-over-year First quarter diluted earnings per share
Health Sciences Reports Record First Quarter 2018 Net Sales and Increases 2018 Outlook first quarter net sales of $292.0 million, an increase of 14.4% quarter diluted earnings per share increased 38.4% to $1.19 per share SALT LAKE CITY--(BUSINESS WIRE)--April 24, 2018--USANA
Read more →USNAUSANA Health Sciences Reports Record Fourth Quarter and Full-Year 2017 Net Sales Record fiscal year net sales of $1.047 billion, an increase of 4.1% Fiscal year net earnings of $62.5 million, or $2.53 per share; Adjusted
USANA Health Sciences Reports Record Fourth Quarter and Full-Year 2017 Net Sales Record fiscal year net sales of $1.047 billion, an increase of 4.1% Fiscal year net earnings of $62.5 million, or $2.53 per share; Adjusted fiscal year net earnings1 of $100.3 million, or $4.06 per
Read more →USNAUSANA Health Sciences Provides Estimated Impact of U.S. Tax Reform SALT LAKE CITY--(BUSINESS WIRE)
Health Sciences Provides Estimated Impact of U.S. Tax Reform SALT LAKE CITY--(BUSINESS WIRE)--January 8, 2018--USANA Health Sciences, Inc. (NYSE: USNA) today reported that it expects to take a one-time non-cash charge to its income statement following U.S. tax reform enacted
Read more →USNAUSANA Health Sciences Reports Third Quarter Financial Results Record third quarter net sales of $261.8 million, an increase of 3.0% year-over-year Number of active Customers 1 at quarter end increased 2.4% to 563,000 Thi
USANA Health Sciences Reports Third Quarter Financial Results Record third quarter net sales of $261.8 million, an increase of 3.0% year-over-year Number of active Customers1 at quarter end increased 2.4% to 563,000 Third quarter EPS of $0.97, or $1.02 excluding incremental ex
Read more →USNAUSANA Health Sciences Announces Appointment of J. Scott Nixon to Board of Directors SALT LAKE CITY--(BUSINESS WIRE)
Health Sciences Announces Appointment of J. Scott Nixon to Board of SALT LAKE CITY--(BUSINESS WIRE)--October 5, 2017--USANA Health Sciences, Inc. (NYSE: USNA) today announced the appointment of J. Scott Nixon to the company's board of directors effective October 5, 2017. Mr. N
Read more →Competitive Position
How USNA ranks across every disease it competes inCompetitive Position is a premium feature
See how USNA ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial